Plain-English translation of NCT02800486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Glioblastoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for brain tumors that have come back or stopped responding to standard treatment. The study uses Cetuximab, a targeted medication designed to attack cancer cells, delivered directly to the tumor through a blood vessel in the brain, combined with radiation therapy. Researchers believe this approach may help stop the tumor from growing and improve survival.
Brain tumors like yours are difficult to treat, and standard therapies don't work well enough — most patients survive only about one year after diagnosis. This medication targets a specific weakness found in many recurring brain tumors, and delivering it directly to the tumor may make it more effective while reducing side effects.
You likely qualify if…
You likely don't qualify if…
You would receive three doses of the medication through a catheter placed in an artery leading to your brain — this happens over multiple visits. Each infusion is preceded by a substance that helps the medication cross the blood-brain barrier. Simultaneously, you will receive focused radiation therapy targeted at your tumor. The trial involves careful monitoring through imaging and blood tests to see how your tumor responds and to watch for any side effects.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States